Sernova Announces Agreement With CCRM to Produce Specialized Cells for the Treatment of Diabetes

- January 26th, 2016

Sernova Corp. (TSXV:SVA, FWB:PSH, OTCQB:SEOVF) entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova’s licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive.

Sernova Corp. (TSXV:SVA, FWB:PSH, OTCQB:SEOVF) entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova’s licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive.
Dr. Philip Toleikis, President and CEO Sernova Corp commented:

Sernova’s Cell Pouch System™ is a novel, preclinically validated and clinically tested platform for multiple types of therapeutic cells, including human islets. Sernova’s CCRM partnership with CCRM’s expertise in developing production processes for cellular therapies is an important step in Sernova’s plan to commercialize an unlimited supply of glucose responsive, insulin producing cells for the Cell Pouch System. Sernova continues to seek out and evaluate optimal unlimited cell sources both internally developed and through corporate partnerships involving stem cell derived, and xenogeneic cell sources. Our manufacturing partnership with CCRM will provide the ability for the scale up production required to ensure successful commercialization of Sernova’s cellular therapies for diabetes.

Click here to view the full press release. 
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *